Pure Biologics (WAR:PUR) EV-to-Revenue : 438.58 (As of May. 31, 2024)

View and export this data going back to 2018. Start your Free Trial

What is Pure Biologics EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Pure Biologics's enterprise value is zł30.26 Mil. Pure Biologics's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was zł0.07 Mil. Therefore, Pure Biologics's EV-to-Revenue for today is 438.58.

The historical rank and industry rank for Pure Biologics's EV-to-Revenue or its related term are showing as below:

WAR:PUR' s EV-to-Revenue Range Over the Past 10 Years
Min: 2.21 Med: 137.21 Max: 1002.62
Current: 438.58

During the past 8 years, the highest EV-to-Revenue of Pure Biologics was 1002.62. The lowest was 2.21. And the median was 137.21.

WAR:PUR's EV-to-Revenue is ranked worse than
92.08% of 1035 companies
in the Biotechnology industry
Industry Median: 7.82 vs WAR:PUR: 438.58

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-05-31), Pure Biologics's stock price is zł6.70. Pure Biologics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was zł0.02. Therefore, Pure Biologics's PS Ratio for today is 335.00.

Pure Biologics EV-to-Revenue Historical Data

The historical data trend for Pure Biologics's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pure Biologics EV-to-Revenue Chart

Pure Biologics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-Revenue

Get a 7-Day Free Trial

26.94

315.51

573.01

71.79

541.01

Pure Biologics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EV-to-Revenue	Get a 7-Day Free Trial															117.19	237.24	698.34	541.01	505.62

Competitive Comparison of Pure Biologics's EV-to-Revenue

For the Biotechnology subindustry, Pure Biologics's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Pure Biologics's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pure Biologics's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Pure Biologics's EV-to-Revenue falls into.

Pure Biologics EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Pure Biologics's EV-to-Revenue for today is calculated as:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	30.262	/	0.069
	=	438.58

Pure Biologics's current Enterprise Value is zł30.26 Mil.
Pure Biologics's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was zł0.07 Mil.

Pure Biologics (WAR:PUR) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Pure Biologics's PS Ratiofor today is calculated as:

PS Ratio	=	Share Price (Today)	/	Revenue per Share (TTM)
	=	6.70	/	0.02
	=	335.00

Pure Biologics's share price for today is zł6.70.
Pure Biologics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was zł0.02.

Pure Biologics EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Pure Biologics's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Pure Biologics (WAR:PUR) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pure Biologics SA (WAR:PUR) » Definitions » EV-to-Revenue

Comparable Companies

Traded in Other Exchanges

PQB:Germany

Address

ul. Dunska 11, Wroclaw, POL, 54-427

Website

http://www.purebiologics.pl

Pure Biologics SA is a Poland based biopharmaceutical company. It invests in the development of new, innovative (non-generic or biosimilar) biological drugs, medical and diagnostic products. It is mainly engaged in the research and development of the biologically active molecule in the drug development process. It specializes in the production and analysis of recombinant proteins and antibodies, contract studies of early product development phases, protein engineering, protein formulation, genomic sequencing, proteomics analysis and bioinformatics. Its projects include cancer immunotherapy, therapy of neurodegenerative diseases, diagnosis of tumors, and other partner projects.

Pure Biologics (WAR:PUR) Headlines

No Headlines